Lipid- and polymer-based nanostructures for cancer theranostics

Summary

This review examines lipid- and polymer-based nanotheranostics that combine cancer imaging and treatment in a single carrier. By packaging a therapeutic agent with an imaging probe, these systems aim to visualize circulation and tissue distribution, monitor delivery as it occurs, and use that information to reduce under- or overdosing. The authors survey formulations paired with magnetic-resonance, radionuclide, or fluorescence imaging and discuss their development in cancer research. The principal argument is that treatment and measurement can be designed together, enabling therapy to be adjusted according to where a carrier travels rather than relying only on population-average dosing. This is significant for personalized medicine and for understanding why a nanomedicine succeeds or fails in an individual. However, the abstract describes a narrative review rather than a clinical demonstration. It provides no systematic search, platform comparison, imaging sensitivity, drug-response correlation, patient outcomes, or evidence that real-time monitoring actually improves dosing or survival. Imaging labels may alter carrier behavior, and signal does not always equal released active drug, but these issues are not resolved. Radiation exposure, toxicity, manufacturing complexity, calibration, regulatory requirements, cost, and clinical workflow integration remain uncertain.